<code id='E66DA9A37B'></code><style id='E66DA9A37B'></style>
    • <acronym id='E66DA9A37B'></acronym>
      <center id='E66DA9A37B'><center id='E66DA9A37B'><tfoot id='E66DA9A37B'></tfoot></center><abbr id='E66DA9A37B'><dir id='E66DA9A37B'><tfoot id='E66DA9A37B'></tfoot><noframes id='E66DA9A37B'>

    • <optgroup id='E66DA9A37B'><strike id='E66DA9A37B'><sup id='E66DA9A37B'></sup></strike><code id='E66DA9A37B'></code></optgroup>
        1. <b id='E66DA9A37B'><label id='E66DA9A37B'><select id='E66DA9A37B'><dt id='E66DA9A37B'><span id='E66DA9A37B'></span></dt></select></label></b><u id='E66DA9A37B'></u>
          <i id='E66DA9A37B'><strike id='E66DA9A37B'><tt id='E66DA9A37B'><pre id='E66DA9A37B'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:99
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA
          Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

          SammyKimballforSTATAredrugpricesprotectedbytheConstitution?WillMedicareembraceAlzheimer’sdiseasetrea

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom